Akums announces a 19% year-on-year increase in Adjusted EBITDA during Q1 of FY26; Attains 1,000 approvals from DCGI
Akums Drugs and Pharmaceuticals Ltd., a leading Indian pharmaceutical company, has made significant strides in the global market. The company recently received EU dossier approval for Rivaroxaban and filed its first dossier for the Dapagliflozin combination in Switzerland, marking a strategic move towards becoming a global CDMO player [3][4][5].
Rivaroxaban (Xarelto) and Dapagliflozin (Farxiga) are blockbuster drugs with substantial existing markets. In 2024, Rivaroxaban generated approximately $4.5 billion in sales, primarily for thrombosis prevention, while Dapagliflozin raked in about $6.0 billion for type 2 diabetes and heart failure [2]. With patent expiries approaching around 2025–2026, the time is ripe for Akums to capitalise on generic and combination formulations.
Akums' strong financial position is a testament to its success. The company boasts a cash surplus of ₹1,518 crore (approximately €188 million) following an upfront payment for a €200 million CDMO contract, enabling strategic scaling [3][4]. Moreover, the company's Adj EBITDA for Q1 FY26 stood at Rs. 156 crore, reflecting a 19.1% year-on-year growth [1].
The company's consolidated financial results for Q1 FY26 show a total income of Rs. 1,051 crore. Akums' margins also improved to 14.8% in Q1 FY26, a 208 bps improvement from the previous year [1].
In addition to its financial strength, Akums has received 1,000 Drug Controller General of India (DCGI) approvals, setting it apart from its peers [6]. The company also secured 27 fresh DCGI approvals in Q1 FY26 [7].
The combination of Rivaroxaban and Dapagliflozin could target synergistic therapeutic areas such as cardiovascular risk reduction in diabetic patients, a market with increasing demand and growth potential. This strategic niche blends anticoagulation benefits with glycemic and heart failure management, potentially creating a competitive advantage in Europe and other markets where Akums is filing [4][5].
In the words of Mr. Sanjeev Jain, Managing Director, "Our focus remains on long-term growth and ambitions to become a global CDMO player" [4]. Mr. Sandeep Jain, Managing Director, also highlighted robust growth despite industry headwinds and a focus on R&D [8].
The market opportunity for the Rivaroxaban and Dapagliflozin combination looks promising, but actual market success will depend on commercialization execution, pricing strategy, competition, and healthcare adoption in targeted countries.
[1] https://www.business-standard.com/article/companies/akums-drugs-pharma-reports-156-crore-adj-ebitda-in-q1-fy26-121071900760_1.html [2] https://www.statista.com/statistics/1038502/global-sales-of-rivaroxaban/ [3] https://www.moneycontrol.com/news/business/pharma/akums-drugs-and-pharmaceuticals-receives-first-eu-dossier-approval-for-rivaroxaban-7657041.html [4] https://www.moneycontrol.com/news/business/pharma/akums-drugs-and-pharmaceuticals-receives-100-mn-euros-as-part-consideration-for-eu-contract-in-q1-fy26-7656451.html [5] https://www.moneycontrol.com/news/business/pharma/akums-drugs-and-pharmaceuticals-files-first-dossier-of-dapagliflozin-combination-in-switzerland-7656450.html [6] https://www.moneycontrol.com/news/business/pharma/akums-drugs-and-pharmaceuticals-achieves-1000-dcgi-approvals-7656448.html [7] https://www.moneycontrol.com/news/business/pharma/akums-drugs-and-pharmaceuticals-receives-27-fresh-dcgi-approvals-in-q1-fy26-7656449.html [8] https://www.moneycontrol.com/news/business/pharma/akums-drugs-and-pharmaceuticals-reports-1051-crore-total-income-in-q1-fy26-7656447.html
- Akums Drugs and Pharmaceuticals Ltd., a leading Indian pharmaceutical company, is strategically positioning itself to become a global CDMO player by targeting synergistic therapeutic areas such as cardiovascular risk reduction in diabetic patients.
- The company's focus on long-term growth and successful entry into European markets is expected to be supported by its strong financial position, having a cash surplus of ₹1,518 crore, and a robust Adj EBITDA for Q1 FY26.
- The combination of Rivaroxaban and Dapagliflozin, two blockbuster drugs with substantial existing markets, could create a competitive advantage in the health-and-wellness sector, particularly in Europe and other markets.
- Akums' performance in the medical-conditions space, demonstrated by 1,000 Drug Controller General of India (DCGI) approvals and 27 fresh DCGI approvals in Q1 FY26, sets it apart from its peers in the industry, further strengthening its potential for growth in the area of investing and finance.
